Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
0.320
-0.005 (-1.48%)
At close: Dec 20, 2024, 4:00 PM
0.330
+0.010 (3.09%)
After-hours: Dec 20, 2024, 7:56 PM EST
Windtree Therapeutics Employees
Windtree Therapeutics had 20 employees as of December 31, 2022. The number of employees decreased by 13 or -39.39% compared to the previous year.
Employees
20
Change (1Y)
-13
Growth (1Y)
-39.39%
Revenue / Employee
n/a
Profits / Employee
-$535,450
Market Cap
2.88M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
iCoreConnect | 70 |
iSpecimen | 53 |
Matinas BioPharma Holdings | 32 |
Scinai Immunotherapeutics | 31 |
LogicMark | 27 |
Processa Pharmaceuticals | 13 |
Onconetix | 12 |
Quoin Pharmaceuticals | 4 |
WINT News
- 12 days ago - Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia - GlobeNewsWire
- 17 days ago - Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction - GlobeNewsWire
- 24 days ago - Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates - GlobeNewsWire
- 2 months ago - Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World - GlobeNewsWire
- 2 months ago - Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan - GlobeNewsWire
- 2 months ago - Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock - GlobeNewsWire
- 3 months ago - Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET - GlobeNewsWire
- 3 months ago - Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock - GlobeNewsWire